Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Celon Pharma SA banner
C

Celon Pharma SA
F:8RP

Watchlist Manager
Celon Pharma SA
F:8RP
Watchlist
Price: 5.43 EUR 8.6%
Market Cap: €277.2m
Write Note Create Alert Ask AI

Wall St Price Targets

8RP Price Targets Summary
Celon Pharma SA

Wall Street analysts forecast 8RP stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 8RP is 4.5 EUR with a low forecast of 3.84 EUR and a high forecast of 5.41 EUR.

8RP Lowest Forecast
Wall Street Target
€3.84
-29% Downside
8RP Average Forecast
Wall Street Target
€4.5
-17% Downside
8RP Highest Forecast
Wall Street Target
€5.41
0% Downside
Lowest Forecast
Price Target
3.84 EUR
29% Downside
Average Forecast
Price Target
4.5 EUR
17% Downside
Highest Forecast
Price Target
5.41 EUR
0% Downside
Celon Pharma SA Competitors:
Price Targets
3
UUU
3U Holding AG
89% Upside
FCNCA
First Citizens BancShares Inc (Delaware)
10% Upside
PACB
Pacific Biosciences of California Inc
60% Upside
3
UUU
3U Holding AG
89% Upside
FCNCA
First Citizens BancShares Inc (Delaware)
10% Upside
PACB
Pacific Biosciences of California Inc
60% Upside

Revenue
Forecast

7% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
7% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 5 years is 13%.

What are analyst estimates?

Gross Profit
Forecast

6% / Year
Past Growth
-16% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
6% / Year
Past Growth
-16% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 9 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 4 years is -16%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
22%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
22%
Average Beat

What are analyst estimates?

Continue 8RP Research

Summary
8RP intrinsic value, competitors valuation, and company profile.
DCF Valuation
8RP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
8RP stock valuation using valuation multiples.
Wall St Estimates
8RP price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
8RP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Celon Pharma SA listings:
WSE • PLN
CLN
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 8RP's stock price target?
Price Target
4.5 EUR

According to Wall Street analysts, the average 1-year price target for 8RP is 4.5 EUR with a low forecast of 3.84 EUR and a high forecast of 5.41 EUR.

What is the Revenue forecast for Celon Pharma SA?
Projected CAGR
13%

Over the last 9 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 5 years is 13%.

What is the Gross Profit forecast for Celon Pharma SA?
Projected CAGR
-16%

Over the last 9 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 4 years is -16%.

Back to Top
ALPHA SPREAD
Follow us
Join 354,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett